EGFR and mismatch repair cancer syndrome 1: Matched therapy based on IHC consisted of trastuzumab for ERBB2 amplification, pembrolizumab for MMR deficiency, pan-ERBB inhibitor for EGFR+, and PI3Kbeta inhibitor for PTEN loss.